The post Bitcoin Crash Triggers Dogecoin, Shiba Inu, and Pepe Selloff appeared on BitcoinEthereumNews.com. Major meme cryptocurrencies suffered significant lossesThe post Bitcoin Crash Triggers Dogecoin, Shiba Inu, and Pepe Selloff appeared on BitcoinEthereumNews.com. Major meme cryptocurrencies suffered significant losses

Bitcoin Crash Triggers Dogecoin, Shiba Inu, and Pepe Selloff

Major meme cryptocurrencies suffered significant losses as Bitcoin fell below $70,000. The meme coin sector saw its market capitalization shrink to $33.5 billion, representing a 10.7% decline in 24 hours.

Dogecoin traded below the $0.10 threshold amid sustained bearish momentum. Shiba Inu recorded a 15.64% price decrease in the last 24 hours. Pepe Coin suffered the steepest decline, falling 17.11%.

The selloff mirrored broader weakness in the cryptocurrency market. Total crypto market capitalization dropped 8.13% to $2.3 trillion. Bitcoin has shed nearly $2 trillion in value since reaching its October all-time high. The leading cryptocurrency now trades at levels last seen during its 2021 peak.

Macroeconomic pressures continue to weigh on digital asset valuations. Risk-averse sentiment has dominated trading activity across all crypto categories.

Dogecoin Tests Critical Support Level

Dogecoin changed hands at $0.0889 after a 14.89% decline in the last 24 hours.  The $0.10 level now represents crucial support territory for Dogecoin. Traders are monitoring this threshold for signs of stabilization or further deterioration.

Derivatives market data reveals weakening institutional interest. Open interest in Dogecoin futures contracted from 1.27 billion to 1.06 billion. This reduction suggests traders are closing positions amid uncertainty.

A sustained hold above $0.09 could enable a recovery attempt. Breaking back above $0.10 would signal a potential trend reversal. However, failure to maintain current levels may trigger additional selling pressure.

Shiba Inu Faces Diminished Burn Activity

Shiba Inu declined 15.64% in the last 24 hours to trade at $0.000005650 at the time of writing. The token’s burn rate decreased by 19.50%, with 1,453,488 SHIB tokens removed from circulation. This represents a sharp slowdown in deflationary activity.

The cryptocurrency is testing support at $0.0000063. This level has provided stability in previous downturns. Maintaining prices above this zone could facilitate a bounce toward $0.0000069.

A breakdown below the current support would expose the next support area. The reduced burn rate suggests decreased community engagement or strategic conservation of tokens. This metric often correlates with market sentiment and trading volumes.

Pepe Coin Approaches Annual Lows

Pepe Coin dropped 17.11% to $0.000003553 over 24 hours. The token has struggled to overcome major resistance despite multiple attempts. Price action suggests consolidation within a triangle pattern.

The meme coin has plunged 41% over the past month. Current trading levels sit near yearly lows. Two weeks of persistent selling have eroded earlier gains substantially.

Technical analysts identify potential support at $0.0000035. This represents a critical defense line for bulls. Bitcoin finding stability around $66,000 could provide relief for Pepe.

A recovery scenario would target the $0.000004 level. However, continued market weakness threatens to establish new lows. The token’s performance remains highly correlated with Bitcoin’s movements.

The trajectories of Dogecoin, Shiba Inu, and Pepe Coin depend on Bitcoin’s stability. A Bitcoin recovery would likely lift meme coins from current levels. Continued downward pressure risks testing deeper support zones.

Source: https://coinpaper.com/14336/shiba-inu-dogecoin-and-pepe-coin-prices-record-major-losses-as-crypto-market-drops-8

Market Opportunity
Pepe Logo
Pepe Price(PEPE)
$0,000003668
$0,000003668$0,000003668
-2,70%
USD
Pepe (PEPE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26